Oxford Nanopore Technologies shares have jumped by 8% today (writing at 12.15pm) after the DNA sequencing specialist reported strong full-year trading that exceeded its revenue guidance.
The FTSE 250 company expects to report 2025 revenues of around £223-224 million, up roughly 22% year-on-year.
This has been driven by broad-based growth across all regions and end markets, with particularly strong performances in clinical (+60%) and BioPharma (+30%) revenues.
Growth was also seen across all product categories, led by the PromethION sequencing platform, which delivered more than 40% year-on-year growth.
The MedTech made further progress on its path to profitability during the year and ended 2025 with around £302m in cash and liquid investments.
Management noted that improving working capital helped leave cash levels ahead of market expectations.
Investor slams ATG over ‘extreme shareholder value destruction’
The update follows a key leadership announcement from last month, when Oxford Nanopore confirmed that Francis Van Parys will take over as chief executive in March 2026, succeeding founder Gordon Sanghera.
Van Parys, who joins from Danaher-owned diagnostics firm Radiometer, brings more than 20 years of senior life sciences leadership experience, while Sanghera will remain in an advisory role through to early 2027 to support the transition.
Sanghera has led the University of Oxford spinout since its founding in 2005, overseeing its 2021 IPO, entry into the FTSE 250 and growth to a market capitalisation of around £1.4 billion.
The company will publish its full-year results on 2nd March, when management will provide further detail on trading performance, strategy execution and outlook.
Its share price now sits at 150.8p, up 7.1% today and over 16% in the last 12 months.